Engineered immune cells take aim at incurable prostate cancer
NCT ID NCT06046040
Summary
This early-stage trial is testing a new type of personalized cell therapy called TmPSMA-02 CAR T cells in men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. Researchers will give 30 participants a single infusion of these specially engineered immune cells to find the safest dose and see if the treatment can shrink tumors. The study focuses first on safety and whether the treatment can be reliably manufactured, while also looking for early signs of effectiveness against this difficult-to-treat cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.